```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable scientific compound extensively used in thrombosis investigations. This Fab fragment selectively targets the glycoprotein IIb/IIIa receptor on thrombocytes , blocking clot formation . Consequently , it's often employed as a method to analyze the pathways underlying clotting and to determine the effectiveness of antiplatelet medications . Supply is typically restricted to research settings.
```
Abciximab Research: Utilizing The C7E3 Fragment and 143653-53-6 in Research Investigations
Ongoing investigation into abciximab, a platelet aggregation inhibitor, frequently utilizes the monoclonal antibody C7E3 and the substance identified as 143653-53-6. These reagents are instrumental for investigating abciximab's mechanism of action, evaluating its therapeutic effect in various clinical settings, and elucidating potential predictors of treatment response. Further study leveraging these specific reagents is predicted to provide valuable insights for enhancing therapeutic strategies related to cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis more info and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Analyzing Potential Opportunities with the Drug Abciximab 143653-53-6 and C7E3
Recent research indicate that this antiplatelet agent (identified as 143653-53-6) holds significant scientific value, particularly when associated with a C7E3 construct. Initial findings suggested that this combination might boost therapeutic results in multiple heart-related contexts. Further exploration is focused on defining the specific mechanism of action between Abciximab and C7E3, involving analysis of platelet cohesion and arterial safeguarding.
- Ongoing investigation work seek to refine administration approaches.
- Laboratory models are were utilized to further assess such propositions.
- Clinical studies will be essential to thoroughly assess clinical efficacy.
```
Abciximab (C7E3) for Research: Quality and Specifications (143653-53-6)
Researchers seeking abciximab for experimental research should rigorously evaluate purity and precise characteristics. Material 143653-53-6 is typically offered as a lyophilized powder and detailed analytical information including verification by LC-MS, potency assays, and endotoxin testing is available. Confirm the supplier's certificate of analysis specifies acceptable ranges for related substances and fulfills relevant QC standards .
High-Purity ReoPro Details & Availability
Acquiring analytical-grade Abciximab, specifically referencing the antibody C7E3 and identified by the chemical number 143653-53-6, requires thorough consideration of its source . This glycoprotein is widely utilized in in vitro investigations , particularly those related to platelet aggregation and thrombosis . Available suppliers offer this reagent in varying volumes, typically ranging from mg to larger commercial supplies. Kindly suggest reviewing the report of analysis to verify purity and suitability for your specific purpose. Furthermore , ensure the shelf life date before obtaining to maintain optimal efficacy .
- Standard Purity: >95%
- Keeping Conditions: -20°C and controlled conditions
- Use : Platelet Aggregation Suppression Studies